Remi Droller - Onxeo SA Executive
| C4X Stock | EUR 0.12 0.01 9.09% |
Executive
Mr. Remi Droller has served as Member of the Board Representative of Kurma Life Science Partners of Bioalliance Pharma SA as of December 16, 2010. He previously served as a Representative of AGF Private Equity on the Company Board of Directors from April 22, 2010 and on the Company Supervisory Board from September 2009. Mr. Droller joined Kurma Life Science Partners as Partner in September 2010 and was previously with CDC Innovation from 2000 to 2003 and with AGF Private Equity from 2003 to 2010 where he was in charge of the development of the Life Sciences investment activity. He serves on the board of several investee companies such as Novagali Pharma and Prosensa since 2010.
| Age | 39 |
| Tenure | 14 years |
| Phone | 33 1 45 58 76 00 |
| Web | https://www.onxeo.com |
Onxeo SA Management Efficiency
The company has return on total asset (ROA) of (0.1108) % which means that it has lost $0.1108 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of (0.3966) %, meaning that it generated substantial loss on money invested by shareholders. Onxeo SA's management efficiency ratios could be used to measure how well Onxeo SA manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Found 4 records | EXECUTIVE Age | ||
| Darren Hribar | Superior Plus Corp | N/A | |
| Danielle DeVoe | NorAm Drilling AS | N/A | |
| Donald Liebentritt | NorAm Drilling AS | 62 | |
| Keith Bowen | NorAm Drilling AS | N/A | |
Management Performance
| Return On Equity | -0.4 | |||
| Return On Asset | -0.11 |
Onxeo SA Leadership Team
Elected by the shareholders, the Onxeo SA's board of directors comprises two types of representatives: Onxeo SA inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Onxeo. The board's role is to monitor Onxeo SA's management team and ensure that shareholders' interests are well served. Onxeo SA's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Onxeo SA's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Elisabeth Carstensen, Director of Alliance Management, Member of the Executive Committee | ||
| Russell Greig, Independent Member of the Board | ||
| Michel Forest, Vice President Quality Qualified Person and Member of the Executive Committee | ||
| Caroline Lemarchand, Preclinical R&D Director, Member of the Executive Committee | ||
| Huiping Jiang, VP Assurance | ||
| Sonia Vallons, Quality Assurance Director, Member of the Executive Committee | ||
| Thomas Hofstaetter, Independent Member of the Board | ||
| MD MPH, CEO Pres | ||
| Delphine Lucas, Regulatory Affairs Director, Member of the Executive Committee | ||
| Francoise Bono, Chief Scientific Officer, Member of the Executive Committee | ||
| Nicolas Trebouta, Member of the Board - Permanent Representative of Financiere de la Montagne | ||
| Audrey LegentilDumery, Director of Human Resources, Member of the Executive Committee | ||
| Judith Greciet, Chief Executive Officer, Member of the Executive Committee, Member of the Board | ||
| Nicolas Fellman, Vice President, Chief Financial Officer, Member of the Executive Committee | ||
| David Solomon, Independent Member of the Board | ||
| Louis Kayitalire, Vice President Head of Research & Development | ||
| Remi Droller, Member of the Board - Representative of Kurma Life Science Partners | ||
| Daniele GuyotCaparros, Independent Member of the Board | ||
| Olivier Beaumont, Chief Medical Officer, Member of the Executive Committee | ||
| Aude Michel, Director of Legal Affairs, Agreements and Licensing, Member of the Executive Committee | ||
| Patrick Langlois, Independent Chairman of the Board | ||
| Graham Dixon, Chief Scientific Officer, Head of Research & Development, Member of the Executive Committee | ||
| Joseph Zakrzewski, Non-Executive Chairman of the Board | ||
| Philippe Maitre, Executive Vice President and Chief of U.S. Operations | ||
| Nicolas Fellmann, CFO Director |
Onxeo Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Onxeo SA a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.4 | |||
| Return On Asset | -0.11 | |||
| Operating Margin | (2.88) % | |||
| Current Valuation | 5.34 M | |||
| Shares Outstanding | 111.06 M | |||
| Shares Owned By Insiders | 13.25 % | |||
| Shares Owned By Institutions | 12.72 % | |||
| Price To Earning | 50.90 X | |||
| Price To Book | 0.48 X | |||
| Price To Sales | 5.35 X |
Pair Trading with Onxeo SA
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Onxeo SA position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Onxeo SA will appreciate offsetting losses from the drop in the long position's value.Moving against Onxeo Stock
| 0.7 | NOVA | Novo Nordisk AS | PairCorr |
| 0.67 | 893 | MITSUBISHI KAKOKI | PairCorr |
| 0.64 | DBPE | Xtrackers LevDAX | PairCorr |
| 0.62 | MBG | Mercedes Benz Group Earnings Call Next Week | PairCorr |
| 0.54 | BFP | BBVA Banco Frances | PairCorr |
The ability to find closely correlated positions to Onxeo SA could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Onxeo SA when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Onxeo SA - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Onxeo SA to buy it.
The correlation of Onxeo SA is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Onxeo SA moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Onxeo SA moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Onxeo SA can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Onxeo SA. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in board of governors. You can also try the Bonds Directory module to find actively traded corporate debentures issued by US companies.
Complementary Tools for Onxeo Stock analysis
When running Onxeo SA's price analysis, check to measure Onxeo SA's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Onxeo SA is operating at the current time. Most of Onxeo SA's value examination focuses on studying past and present price action to predict the probability of Onxeo SA's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Onxeo SA's price. Additionally, you may evaluate how the addition of Onxeo SA to your portfolios can decrease your overall portfolio volatility.
| Piotroski F Score Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals | |
| Cryptocurrency Center Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency | |
| Watchlist Optimization Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm | |
| Money Managers Screen money managers from public funds and ETFs managed around the world | |
| Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios | |
| ETF Categories List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments |